Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 27;36(7):doac095. doi: 10.1093/dote/doac095

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 5 — Significance of lymphatic metastases in patients with complete response of the primary tumor. Comparison of the different groups of patients. The best OS can be achieved in patients with pCR (ypT0ypN0). Residual tumor in lymphnodes in patients with complete response of the primary tumor (non-CR T0N+) is associated with a poor survival probability, which is comparable unfavorable as in patients with non-CR in the primary tumor-site and with lymphatic spread (non-CR T+N+). Patients without lymphnode metastases (non-CR T+N0) have only a slightly impaired OS-probability compared with patients with pCR. (A) All patients with EC after neoadjuvant treatment (EAC and ESCC combined) (Median OS—pCR: Median OS not reached, non-CR T0N+: 22.0 months (95%-CI: 10.4–33.5), non-CR T+N-: Median OS not reached, non-CR T+N+: 23.0 months (95%-CI: 15.3–30.7), P-values: pCR vs. non-CR T0N+: 0.001, pCR vs. non-CR T+N-: 0.055, pCR vs. non-CR T+N+: <0.001, non-CR T0N+ vs. non-CR T+N-: 0.016; non-CR T0N+ vs. non-CR T+N+: 0.956; non-CR T+N- vs. non-CR T+N+: <0.001), (B) in patients with EAC (Median OS—pCR: Median OS not reached, non-CR T0N+: 43.0 months (95%-CI: not estimable), non-CR T+N-: Median OS not reached, non-CR T+N+: 23.0 months (95%-CI: 15.8–30.2), P-values: pCR vs. non-CR T0N+: 0.025, pCR vs. non-CR T+N-: 0.129, pCR vs. non-CR T+N+: <0.001, non-CR T0N+ vs. non-CR T+N-: 0.108; non-CR T0N+ vs. non-CR T+N+: 0.868; non-CR T+N- vs. non-CR T+N+: <0.001) and (C) in patients with ESCC (Median OS—pCR: Median OS not reached, non-CR T0N+: 10.0 months (95%-CI: 0.0–22.7), non-CR T+N-: 31.0 months (95%-CI: 14.3–47.7), non-CR T+N+: 10.0 months (95%-CI: 2.8–17.2), P-values: pCR vs. non-CR T0N+: 0.017, pCR vs. non-CR T+N-: 0.042, pCR vs. non-CR T+N+: <0.002, non-CR T0N+ vs. non-CR T+N-: 0.419; non-CR T0N+ vs. non-CR T+N+: 0.827; non-CR T+N- vs. non-CR T+N+: <0.380). pCR (ypT0ypN0) patients with signs of postneoadjuvant regression in lymphnodes have the same OS-probability compared with patients without signs of regression in the examined lymphnodes (P = 0.975). (D) In patients with EAC (P = 0.919). (E) In patients with ESCC (P = 0.828).